Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial — PLATFORM  

Adenocarcinoma of the Stomach Clinical Trial

Official title: Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.

Clinical Trial Description

This is a prospective, open label, multicentre, randomised phase II clinical trial. An adaptive trial design is proposed to allow ineffective treatments to be discontinued early, and to potentially add novel treatment arms as the trial progresses. Patients will initially receive standard chemotherapy for their locally advanced or metastatic oesophago-gastric adenocarcinoma, according to local practice based upon their HER-2 status (tested locally). In order to be eligible for trial entry, HER-2 negative patients should have received a platinum-fluoropyrimidine based chemotherapy doublet of either cisplatin + capecitaine (CX), oxaliplatin + capecitabine (CAPOX), or 5FU + oxaliplatin (FOLFOX) (Arm A), whilst HER-2 positive patients (IHC 3+ or IHC 2+ and FISH positive) should have received cisplatin in combination with either capecitabine or 5-FU (CX or CF) plus trastuzumab chemotherapy (Arm B). Potentially eligible patients will be registered with the trials office whilst undergoing first line chemotherapy. Patients will become eligible for trial recruitment and randomisation after 18 weeks standard chemotherapy with stable disease (SD) or better on the end-of-treatment CT scan. Please note: if your patient has been receiving a regimen delivered every three weeks (e.g. CX) they should have completed 6 cycles. If your patient has been receiving a regimen delivered every 2 weeks (e.g. FOLFOX) they should have received 9 cycles of treatment. Eligible patients will then be randomised according to HER-2 status as follows: - HER-2 positive patients (~20%) will be assigned maintenance single-agent trastuzumab (current UK standard) - HER-2 negative patients (~80%) will be randomised 1:1 between surveillance (current UK standard) and maintenance capecitabine. Patients will be stratified according to: centre region, disease extent and performance status (0 versus 1 versus 2). Review of patients will occur every 4 weeks in the surveillance arm. In maintenance therapy arms, patients will be reviewed every 3 or every 4 weeks depending upon the treatment strategy. CT assessments of response will occur every 12 weeks (3 months) in all arms of the trial. Treatment will be continued until disease progression, unacceptable toxicity, or patient withdrawal for another reason. The trial is being run from the RM GI and Lymphoma CTU with Professor David Cunningham as the Chief Investigator (CI). Effective arms in the phase II portion of the trial may be taken forward into a phase III maintenance trial powered for overall survival. It is also hoped that, as more robust data becomes available for other biomarker-selected populations (e.g. MET-positive, FGFR-amplified), it may be possible to amend the overall trial design to incorporate these biomarker-targeted maintenance therapies in the HER-2 negative population. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Gastro-oesophageal Junction
• Adenocarcinoma of the Oesophagus
• Adenocarcinoma of the Stomach

• NCT number: NCT02678182
• Study type: Interventional
• Source: Royal Marsden NHS Foundation Trust
• Contact: Sue Cromarty
• Phone: 0208 661 3807
• Email: PLATFORM@rmh.nhs.uk
• Status: Recruiting
• Phase: Phase 2
• Start date: February 2015
• Completion date: June 2027